Eric Reiman, MD
Executive Director of the Banner Alzheimer’s Institute (BAI), Chief Executive Officer for Banner Research, Clinical Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and Director of the Arizona Alzheimer’s Consortium, Banner Alzheimer’s Institute
Dr. Reiman, M.D. is Executive Director of the Banner Alzheimer’s Institute (BAI), Chief Executive Officer for Banner Research, Clinical Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and Director of the Arizona Alzheimer’s Consortium. His research interests include brain imaging, genomics, and their use in the unusually early detection and tracking of Alzheimer’s disease (AD), the evaluation of genetic and non-genetic risk factors, and the accelerated evaluation of treatments to prevent AD.
Dr. Reiman received an AB Duke In-Class Scholarship, his undergraduate and medical degrees, and most of his psychiatry residency training at Duke University. He completed his residency training and joined the faculty at Washington University in St. Louis, where he helped to advance positron emission tomography and human brain mapping research, and moved to Arizona in 1988. Over the years, he and his colleagues introduced image analysis techniques that have helped to revolutionize the study of the human mind and brain. They have used advanced imaging techniques to help characterize brain regions are involved in emotion, memory, pain, hunger and satiation and the predisposition to anxiety disorders, memory disorders and obesity. They also reported the first genome-wide association and neuronal transcriptomic studies of AD and the first genome-wide association study of normal human memory, Since 1993, Dr. Reiman and his Arizona colleagues have been using imaging techniques to detect and track brain changes in cognitively normal people with two copies, one copy and no copies of the apolipoprotein E (APOE) e4 allele, the major AD susceptibility gene, evaluate genetic and non-genetic risk factors for the disorder, and provide a springboard for genomic, transcriptomic, neuropathological and basic neuroscientific studies of AD. In partnership with researchers at the University of Antioquia, he and his colleagues have extended their efforts to the study of mutation carriers and non-carriers from the world’s largest autosomal dominant AD kindred in Colombia.
Dr. Reiman is the author of more than 200 publications and the principal investigator of several NIH research grants. He and his colleagues have used imaging techniques to detect and track some of the earliest brain changes associated with the genetic risk of AD, and they have suggested how imaging techniques could be used in at-risk people to evaluate promising Alzheimer’s prevention therapies without having to study many healthy volunteers or wait many years to determine if they go on to develop symptoms.
Under Dr. Reiman’s direction, researchers and institutional leaders established the Arizona Alzheimer’s Consortium, the leading model of statewide collaboration in AD research. In 2006, he and his colleagues established the BAI, which is intended to accelerate the evaluation of promising AD prevention therapies, help to establish a new standard of care for patients and families, and forge a model of collaboration in biomedical research. In addition to his other responsibilities, he oversees research at Banner Health, one of the largest non-profit health systems in the United States. Dr. Reiman, Dr. Pierre Tariot and their colleagues have developed the “Alzheimer’s Prevention Initiative” (API) to evaluate amyloid-modifying treatments in cognitively normal people who, based on their age and genetic background, are at the highest imminent risk of AD symptoms, to help establish the biomarker endpoints and accelerated regulatory approval pathway needed to rapidly evaluate the range of promising prevention therapies, and to provide exceptionally large AD Prevention Registries as a shared resource for these and other prevention trials. Preparation for the API’s first prevention trial is underway in Colombia and the U.S. It will evaluate the efficacy and safety of the amyloid immunization therapy crenezumab in the prevention of AD, further test the amyloid hypothesis, and provide data and samples to the research community soon after the study is completed. The $100 million trial is supported by National Institute on Aging, the Banner Alzheimer’s Foundation, and Genentech.